HIV and hepatitis C coinfection.

Area of Science:

• Hepatology
• Infectious Diseases
• Immunology

Background:

• HIV/HCV coinfection presents a substantial global health burden, particularly in the Asia-Pacific region.
• Coinfected individuals face accelerated liver disease progression, leading to cirrhosis, liver failure, and hepatocellular carcinoma.
• Altered immune responses and increased risk of hepatotoxicity from highly active antiretroviral therapy (HAART) are concerns in coinfected patients.

Purpose of the Study:

• To review the challenges and current management strategies for HIV/HCV coinfection.
• To emphasize the importance of early diagnosis and treatment assessment for HCV in coinfected individuals.
• To discuss the implications of coinfection on treatment outcomes and the potential of novel therapies.

Main Methods:

• Review of current literature on HIV/HCV coinfection management.
• Analysis of treatment outcomes with standard pegylated interferon and ribavirin therapy.
• Discussion of factors influencing treatment response and toxicity.

Main Results:

• HCV treatment response rates in coinfected individuals are 10-15% lower than in HCV monoinfection.
• Drug interactions and toxicity complicate HCV treatment in coinfected patients.
• Baseline factors and on-treatment monitoring aid in predicting and individualizing therapy.

Conclusions:

• HCV treatment is often recommended before initiating HAART to mitigate drug interactions and hepatotoxicity.
• Early diagnosis of both HIV and HCV is essential for effective management.
• Emerging therapies like protease and polymerase inhibitors offer future treatment possibilities for HIV/HCV coinfected individuals.